ORGS: Orgenesis, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 81.59
Enterprise Value ($M) 76.70
Book Value ($M) 25.80
Book Value / Share 1.77
Price / Book 3.16
NCAV ($M) -1.37
NCAV / Share -0.09
Price / NCAV -59.47

Profitability (mra)
Return on Invested Capital (ROIC) -0.88
Return on Assets (ROA) -0.37
Return on Equity (ROE) -1.17

Liquidity (mrq)
Quick Ratio 0.96
Current Ratio 0.53

Balance Sheet (mrq) ($M)
Current Assets 13.74
Assets 47.03
Liabilities 15.11
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 10.09
Operating Income -11.23
Net Income -12.37
Earnings Per Share Basic 1.28
Earnings Per Share Diluted 1.31

Cash Flow Statement (mra) ($M)
Cash From Operations -3.83
Cash from Investing -3.40
Cash from Financing -3.40

Source:
Fintel.io

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
2018-03-22 13D/A Universite Libre De Bruxelles 4.03 -60.00
2018-01-25 13D Belenger Olivier 0.00 -100.00
2018-01-25 13D Theodorus Sca 0.00 -100.00
2018-01-25 13D Theodorus Ii Sa 0.00 -100.00
2017-12-06 13D/A Bultot Hugues 6.61 -87.00

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

Source:
Fintel.io

Date Insider Trades Code Shares Value

Source:
Fintel.io

File Date Form SEC Filings
2018-07-17 10-Q ORGS / Orgenesis, Inc. FORM 10-Q (Quarterly Report)
2018-04-16 10-Q ORGS / Orgenesis, Inc. FORM 10-Q (Quarterly Report)

Source:
Fintel.io

Similar Companies
OPHT – Ophthotech Corp OPK – Opko Health, Inc.
OREX – Orexigen Therapeutics, Inc. ORMP – Oramed Pharmaceuticals, Inc.
OSIR – Osiris Therapeutics, Inc.


Financial data and stock pages provided for FREE by
Fintel.io